ایک حادثہ المناک]مولانا ظفر احمد خاں[
۱۳؍دسمبر ۱۹۷۹ء جمعرات کی شب میں ایک بجے مولانا محمد ظفر احمد خاں صاحب رحلت فرماگئے۔ اناﷲ واناالیہ راجعون۔ ۱۹۳۸ء میں یہ ادارہ قائم ہوا۔ مولانا مرحوم ۱۹۳۹ء میں ندوۃ المصنفین میں بحیثیت کارکن ومنیجر تشریف لائے۔ موصوف کارسالہ برہان اورادارہ ندوۃ المصنفین سے دیرینہ تعلق تھا۔مرحوم کا حضرت مفتی صاحب سے تعلق چالیس ۴۰ سال رہا۔ اوراسی دوران جب سے دفتر کی ذمہ داریاں میرے سپرد کی گئی تھیں وہ ۱۹۶۸ء تھا، زیادہ تراسی وقت سے میرا مرحوم سے قُرب رہا۔موصوف پُرخلوص نیک دل انسان تھے اور وفاداری ان کے مزاج میں بے پناہ پائی جاتی تھی۔موصوف اپنی خود ایک مثال تھے۔ادارہ ندوۃ المصنفین کے وفادار اورایک اعلیٰ معیار کے کارکنوں میں ان کاشمار تھا۔مولوی صاحب میرے لیے سہارا اور ڈھارس تھے کیونکہ مجھ کو اُن سے حوصلہ افزائی اور تقویت حاصل تھی۔ مولوی صاحب کی جدائی میرے واسطے ایک بھیانک انقلاب ہے۔مجھ کویہ دلی صدمہ پہنچا ہے دعافرمائیں کہ مزید ذمہ داریاں سنبھالنے کی اﷲ تعالیٰ مجھ کو بہترین صلاحیتوں سے نوازدیں۔آمین ثم آمین۔
مولوی صاحب اس جہانِ فانی سے رخصت ہونے کے چھ گھنٹے قبل تک رسالہ برہان کاکام انجام دیتے رہے۔ [منیجر ندوۃ المصنفین دہلی، جنوری ۱۹۸۰ء]
This research aims to design an electric panel monitoring system using the Internet of Things technology in company buildings so that consumers can monitor real-time electricity consumption. The energy consumption monitoring method that we propose uses PM2100 by implementing a real-time monitoring function of the power consumption of a 3-phase electric panel. The monitoring system implementation results show that the value is very close to measuring the digital multimeter measuring instrument. The monitoring system produces a current measurement accuracy of 97.38% with an error of 2.62%, while the 3-phase voltage measurement error is 0.616%. This system design helps companies obtain information faster to be considered data to improve efficiency in the Company.
Drug development has multiple stages of drug designing and evaluation in pharmacological models for desired clinical outcomes. The unmet need to completely eradicate cancer and leishmaniasis drives researchers to continue the struggle for safer and effective medicines. Along these lines, a library of 78 organic synthetic compounds including organotin (IV) (39), indoline (15), hydrazide (4), diazole (2) and ferrocene (18) derivatives were studied against Leishmania and cancer using in vitro, in silico and in vivo models. Cytotoxicity against DU145, THP-1 and isolated lymphocytes was shown by 36 (> 70%), 21 (> 50-70%), and 18 (least IC50 2.23 µg/ml) organotins and 1 (75.72%), 4 (50.2-82.3%) and 2 (least IC50 13 µg/ml) indolines, respectively. Only 5 (50.08-81.7%) hydrazides/diazoles and 9 (least IC50 6.66 µg/ml) ferrocenes were cytotoxic to THP-1 cells and lymphocytes, respectively. A total of 38 (least MIC 0.0122 µg/disc) organotins, 1 (least MIC 3.125 µg/disc) indoline, 3 (least MIC 1.5625 µg/disc) diazole/hydrazides and 17 (least MIC 0.74 µg/disc) ferrocenes demonstrated protein kinase (PK) inhibition activity in Streptomyces 85E. Next, in silico analysis of selected 36 organotin (IV) compounds, comparatively more cytotoxic to cancer cells, showed that these were druglike to mid structures, have low to high blood brain barrier penetration and human intestinal absorption (caco2 cell permeability 17.6-35.09 nm/sec) and were metabolized by phase I and phase II reactions. Organotins were also predicted to target multiple enzymes, transcription factors, receptors, transporters, ion channels and other proteins. Subsequently, in vitro cytotoxicity analysis in prostate cancer cell lines and fibroblasts provided least IC50 values of 0.17 µM (PC3M) and 1.67 µM (fibroblasts) for triphenyltin (IV); 0.63 µM (PC3M) and 0.12 µM (fibroblasts) for tributyltin (IV); 0.33 µM (PC3M) and 2.55 µM (fibroblasts) for dibutyltin (IV) and 6.06 µM (PC3M) and 4.29 µM (fibroblasts) for tribenzyltin (IV) compounds after 72 h of treatment. Eventually, in-depth study of two most active compounds namely dibutylstannanediyl (2Z,2’Z)-bis(4(benzylamino)-4-oxobut-2-enoate (Ch-620) and triphenylstannyl 2-(benzylcarbamoyl) benzoate (Ch-319), showed that both compounds were more cytotoxic to prostate cancer and melanoma cells as compared to normal cells, restricted their colony forming capacity and migration, induced cell cycle arrest and caspase mediated apoptosis and disrupted associated regulatory proteins. Ch-620 resulted in phosphorylation of p38 MAPK and ERK1/2, upregulation of PPARα, decreased expression of SMAD4 and ITGB5 and reduced tumor proliferation as observed by proteomics, in vitro and in vivo xenograft studies. Treatment of cancer cells and transgenic Pten knockout mice with Ch-319 downregulated PI3K/Akt signaling associated with elevation of FOXO3a expression. In addition, Ch-319 decreased expression of epithelial-mesenchymal transition markers Ncadherin and Vimentin with concomitant increase in E-cadherin in in vitro. Immunohistochemical examination of tumor sections also depicted reduction of proliferation markers. Moreover, evaluation of 78 compounds against Leishmania tropica kwh showed that 37, 5 and 1 organotin, indoline and ferrocene compounds, respectively inhibited growth of promastigotes. The selected 43 compounds predominantly organotin (IV) derivatives, halted the growth of Leishmania promastigotes partially by producing reactive oxygen species. Antileishmanial activity was reduced by 4.1-6.9 and 1.4-7.96% in triphenyltin (IV), 3.3-14.22 and 6.3-11.2% in tribenzyltin (IV), 5.2-34.38 and 1.838.2% in tributyltin (IV) and 7.9-15.7 and 5.2-15.4% in dibutyltin (IV) compounds in the presence of sodium azide and mannitol, respectively. Indolines and ferrocenes demonstrated antileishmanial activity reduction maximally in the presence of mannitol by 5.3 and 6.22%, respectively. Considering all these results, it is proposed that Ch-319 and Ch-620 have potential to be developed as anticancer agents against prostate cancer. Furthermore, organotin (IV) compounds in particular are also potent antileishmanial agents and detailed analysis on their mechanism is recommended.